Art. -Nr.: HY-121255

(-)-Cryptopleurine

(Synonyms: (R)-Cryptopleurine; NSC 19912)

Kundenbewertung

Based on 1 Customer Validation

(–)-Cryptopleurine is an alkaloid that has been found in Lauraceae and has diverse biological activities. It inhibits the growth of human A375 melanoma, A431 epidermoid carcinoma, A549 lung, MES-SA uterine sarcoma, and MCF-7 breast cancer cells (IC₅₀=3 nM for all).2 (–)-Cryptopleurine inhibits hypoxia-induced gene expression in a hypoxia response element (HRE) reporter assay (IC₅₀=8.7 nM).3 (–)-Cryptopleurine (500 μg/mL) prevents lesion formation in tobacco (N. tabacum) plants infected with tobacco mosaic virus (TMV). It also inhibits protein synthesis by yeast and mammalian ribosomes.

Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.

Reinheit: 98%
CAS. Nr.: 482-22-4
Formel: C₂₄H₂₇NO₃
Molecular Weight:377.48

Speicherung:

Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month

(-)-Cryptopleurine Chemical Structure

CAS. Nr.: 482-22-4

Größe

Preis

Verfügbarkeit

Menge

Amount: USD 0.00

* Bitte wählen Sie Menge, bevor Sie Artikel hinzufügen.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biologische Aktivität
- Beschreibung
- Cellular Effect
Chemical Information
Reinheit & Dokumentation
Verweise
Calculators
Help & FAQs
Classifications
Bioz

Biologische Aktivität

Beschreibung

Cellular Effect

Cell Line	Type	Value	Description	References
A-375	IC₅₀	0.003 μM Compound: (-)-2	Cytotoxicity against human melanoma, A375 cells Cytotoxicity against human melanoma, A375 cells	[PMID: 16236503]
A-375	IC₅₀	1.2 nM Compound: (-)-1	Antiproliferative activity against human A375 cells after 72 hrs by ATPlite assay Antiproliferative activity against human A375 cells after 72 hrs by ATPlite assay	[PMID: 25499434]
A-431	IC₅₀	0.003 μM Compound: (-)-2	Cytotoxicity against human epidermoid carcinoma, A431 cells Cytotoxicity against human epidermoid carcinoma, A431 cells	[PMID: 16236503]
A549	GI₅₀	<0.001 μM Compound: 36	Antiproliferative activity against human A549 cells after 72 hrs by MTT assay Antiproliferative activity against human A549 cells after 72 hrs by MTT assay	[PMID: 22417638]
A549	GI₅₀	1.38 nM Compound: R-cryptopleurine	Anticancer activity against human A549 cells after 72 hrs by sulforhodamine B assay Anticancer activity against human A549 cells after 72 hrs by sulforhodamine B assay	[PMID: 21668000]
A549	IC₅₀	0.003 μM Compound: (-)-2	Cytotoxicity against human lung carcinoma, A549 cells Cytotoxicity against human lung carcinoma, A549 cells	[PMID: 16236503]
A549	IC₅₀	0.94 nM Compound: 2	Cytotoxicity against human A549 cells assessed as growth inhibition after 72 hrs by SRB assay Cytotoxicity against human A549 cells assessed as growth inhibition after 72 hrs by SRB assay	[PMID: 26393416]
A549	IC₅₀	1.38 nM Compound: cryptopleurine	Cytotoxicity against human A549 cells after 2 hrs by methylene blue staining-based spectrophotometric analysis Cytotoxicity against human A549 cells after 2 hrs by methylene blue staining-based spectrophotometric analysis	[PMID: 22823514]
A549	IC₅₀	1.9 nM Compound: (-)-1	Antiproliferative activity against human A549 cells after 72 hrs by ATPlite assay Antiproliferative activity against human A549 cells after 72 hrs by ATPlite assay	[PMID: 25499434]
A549	IC₅₀	1.9 nM Compound: cryptopleurine	Cytotoxicity against human A549 cells assessed as cell viability after 48 hrs by SRB assay Cytotoxicity against human A549 cells assessed as cell viability after 48 hrs by SRB assay	[PMID: 22823514]
AGS	IC₅₀	8.7 nM Compound: 1	Inhibition of hypoxia-induced HIF1 activation in human AGS cells after 16 hrs by pGL3-HRE-luciferase reporter gene assay Inhibition of hypoxia-induced HIF1 activation in human AGS cells after 16 hrs by pGL3-HRE-luciferase reporter gene assay	[PMID: 16872154]
BT-20	IC₅₀	0.003 μM Compound: (-)-2	Cytotoxicity against human breast carcinoma, BT20 cells Cytotoxicity against human breast carcinoma, BT20 cells	[PMID: 16236503]
BUD-8	IC₅₀	0.006 μM Compound: (-)-2	Cytotoxicity against human fibroblast, BUD8 cells Cytotoxicity against human fibroblast, BUD8 cells	[PMID: 16236503]
CAKI-1	IC₅₀	0.86 nM Compound: 2	Cytotoxicity against human Caki1 cells assessed as growth inhibition after 72 hrs by SRB assay Cytotoxicity against human Caki1 cells assessed as growth inhibition after 72 hrs by SRB assay	[PMID: 26393416]
CL1-0	IC₅₀	5 nM Compound: cryptopleurine	Cytotoxicity against human CL1-0 cells assessed as cell viability after 48 hrs by SRB assay Cytotoxicity against human CL1-0 cells assessed as cell viability after 48 hrs by SRB assay	[PMID: 22823514]
Daudi	IC₅₀	0.002 μM Compound: (-)-2	Cytotoxicity against human Burkitt lymphoma, DAUDI cells Cytotoxicity against human Burkitt lymphoma, DAUDI cells	[PMID: 16236503]
DU-145	GI₅₀	1.59 nM Compound: R-cryptopleurine	Anticancer activity against human DU145 cells after 72 hrs by sulforhodamine B assay Anticancer activity against human DU145 cells after 72 hrs by sulforhodamine B assay	[PMID: 21668000]
DU-145	IC₅₀	1.59 nM Compound: cryptopleurine	Cytotoxicity against human DU145 cells after 2 hrs by methylene blue staining-based spectrophotometric analysis Cytotoxicity against human DU145 cells after 2 hrs by methylene blue staining-based spectrophotometric analysis	[PMID: 22823514]
HCT-116	IC₅₀	0.7 nM Compound: (-)-1	Antiproliferative activity against human HCT116 cells after 72 hrs by ATPlite assay Antiproliferative activity against human HCT116 cells after 72 hrs by ATPlite assay	[PMID: 25499434]
HCT-116	IC₅₀	1.04 nM Compound: 2	Cytotoxicity against human HCT116 cells assessed as growth inhibition after 72 hrs by SRB assay Cytotoxicity against human HCT116 cells assessed as growth inhibition after 72 hrs by SRB assay	[PMID: 26393416]
HCT-15	IC₅₀	0.003 μM Compound: (-)-2	Cytotoxicity against human colon carcinoma, HCT15 cells Cytotoxicity against human colon carcinoma, HCT15 cells	[PMID: 16236503]
HCT-8	GI₅₀	1.09 nM Compound: R-cryptopleurine	Anticancer activity against human HCT8 cells after 72 hrs by sulforhodamine B assay Anticancer activity against human HCT8 cells after 72 hrs by sulforhodamine B assay	[PMID: 21668000]
HCT-8	IC₅₀	1.91 nM Compound: cryptopleurine	Cytotoxicity against human HCT8 cells after 2 hrs by methylene blue staining-based spectrophotometric analysis Cytotoxicity against human HCT8 cells after 2 hrs by methylene blue staining-based spectrophotometric analysis	[PMID: 22823514]
HepG2 2.2.15	IC₅₀	6.3 nM Compound: Cryptopleurine	Cytotoxicity against human HepG2(2.2.15) cells assessed as cell growth inhibition Cytotoxicity against human HepG2(2.2.15) cells assessed as cell growth inhibition	[PMID: 29317151]
HL-60	GI₅₀	<0.001 μM Compound: 36	Antiproliferative activity against human HL60 cells after 72 hrs by SRB assay Antiproliferative activity against human HL60 cells after 72 hrs by SRB assay	[PMID: 22417638]
HT-1376	IC₅₀	0.004 μM Compound: (-)-2	Cytotoxicity against human bladder carcinoma, HT1376 cells Cytotoxicity against human bladder carcinoma, HT1376 cells	[PMID: 16236503]
HUVEC	GI₅₀	11 nM Compound: R-cryptopleurine	Toxicity against HUVEC Toxicity against HUVEC	[PMID: 21668000]
KB	GI₅₀	1.51 nM Compound: R-cryptopleurine	Anticancer activity against human KB cells after 72 hrs by sulforhodamine B assay Anticancer activity against human KB cells after 72 hrs by sulforhodamine B assay	[PMID: 21668000]
KB	IC₅₀	1.51 nM Compound: cryptopleurine	Cytotoxicity against human KB cells after 2 hrs by methylene blue staining-based spectrophotometric analysis Cytotoxicity against human KB cells after 2 hrs by methylene blue staining-based spectrophotometric analysis	[PMID: 22823514]
KHOS/NP	IC₅₀	0.01 μM Compound: (-)-2	Cytotoxicity against human osteosarcoma, KHOS-NP cells Cytotoxicity against human osteosarcoma, KHOS-NP cells	[PMID: 16236503]
MAT-Ly-Lu	IC₅₀	0.003 μM Compound: (-)-2	Cytotoxicity against rat prostate carcinoma, MatLyLu cells Cytotoxicity against rat prostate carcinoma, MatLyLu cells	[PMID: 16236503]
MCF7	IC₅₀	0.003 μM Compound: (-)-2	Cytotoxicity against human breast carcinoma, MCF7 cells Cytotoxicity against human breast carcinoma, MCF7 cells	[PMID: 16236503]
MDA-MB-231	IC₅₀	0.89 nM Compound: 2	Cytotoxicity against human MDA-MB-231 cells assessed as growth inhibition after 72 hrs by SRB assay Cytotoxicity against human MDA-MB-231 cells assessed as growth inhibition after 72 hrs by SRB assay	[PMID: 26393416]
MES-SA	IC₅₀	0.003 μM Compound: (-)-2	Cytotoxicity against human uterine sarcoma, MES-SA cells Cytotoxicity against human uterine sarcoma, MES-SA cells	[PMID: 16236503]
MES-SA/Dx5	IC₅₀	0.003 μM Compound: (-)-2	Cytotoxicity against human uterine sarcoma, MES-SA-Dx5 cells derived from MES-SA Cytotoxicity against human uterine sarcoma, MES-SA-Dx5 cells derived from MES-SA	[PMID: 16236503]
MRC5	IC₅₀	14 nM Compound: cryptopleurine	Cytotoxicity against human MRC5 cells assessed as cell viability after 48 hrs by SRB assay Cytotoxicity against human MRC5 cells assessed as cell viability after 48 hrs by SRB assay	[PMID: 22823514]
NAMALVA	IC₅₀	2.6 nM Compound: (-)-1	Antiproliferative activity against human NAMALWA cells after 72 hrs by ATPlite assay Antiproliferative activity against human NAMALWA cells after 72 hrs by ATPlite assay	[PMID: 25499434]
PA-1	IC₅₀	0.002 μM Compound: (-)-2	Cytotoxicity against human ovarian teratocarcinoma, PA1 cells Cytotoxicity against human ovarian teratocarcinoma, PA1 cells	[PMID: 16236503]
PC-3	IC₅₀	2.55 nM Compound: 2	Cytotoxicity against human PC3 cells assessed as growth inhibition after 72 hrs by SRB assay Cytotoxicity against human PC3 cells assessed as growth inhibition after 72 hrs by SRB assay	[PMID: 26393416]
PC-9	IC₅₀	5.5 nM Compound: cryptopleurine	Cytotoxicity against human PC9 cells assessed as cell viability after 48 hrs by SRB assay Cytotoxicity against human PC9 cells assessed as cell viability after 48 hrs by SRB assay	[PMID: 22823514]
Ramos	IC₅₀	0.003 μM Compound: (-)-2	Cytotoxicity against human Burkitt lymphoma, RAMOS cells Cytotoxicity against human Burkitt lymphoma, RAMOS cells	[PMID: 16236503]
SK-HEP1	IC₅₀	0.83 nM Compound: 2	Cytotoxicity against human SKHEP1 cells assessed as growth inhibition after 72 hrs by SRB assay Cytotoxicity against human SKHEP1 cells assessed as growth inhibition after 72 hrs by SRB assay	[PMID: 26393416]
SNU-638	IC₅₀	1.26 nM Compound: 2	Cytotoxicity against human SNU638 cells assessed as growth inhibition after 72 hrs by SRB assay Cytotoxicity against human SNU638 cells assessed as growth inhibition after 72 hrs by SRB assay	[PMID: 26393416]

Chemical Information

CAS. Nr. 482-22-4
Appearance Solid
Molecular Weight 377.48
Formel C₂₄H₂₇NO₃
Color White to off-white
SMILES

COC1=CC2=C3C=C(C(OC)=CC3=C4C[C@]5(CCCCN5CC4=C2C=C1)[H])OC
Synonyms

(R)-Cryptopleurine; NSC 19912
Versand

Room temperature in continental US; may vary elsewhere.

Speicherung

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	6 months
	-20°C	1 month

Reinheit & Dokumentation

Select Batch:

Reinheit: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (271 KB)
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Korean - KR (252 KB)
- Portuguese - PT (252 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

Verweise

[1]. Cai, et al. Phenanthroquinolizidine alkaloids from the roots of Boehmeria pannosa potently inhibit hypoxia-inducible factor-1 in AGS human gastric cancer cells. J. Nat. Prod. 69(7), 1095-1097 (2006).

Calculators

Molaritätsrechner

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Konzentration Konzentration

Volumen Volumen

Molecular Weight Molecular Weight

Verdünnungsrechner

Konzentration _{(Stammlösung)} × Volumen _{(Stammlösung)} = Konzentration _{(Ziellösung)} × Volumen _{(Ziellösung)}

Konzentration _{(Stammlösung)} Konzentration _{(Stammlösung)}

Volumen _{(Stammlösung)} Volumen _{(Stammlösung)}

Konzentration _{(Ziellösung)} Konzentration _{(Ziellösung)}

Volumen _{(Ziellösung)} Volumen _{(Ziellösung)}

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Keywords

Produktname:
Art. -Nr.:
Menge:
MCE Japan Authorized Agent:

Produktname:
CAS. Nr.:
Species:
Reinheit:
Menge: